Figure 2.

SRGN maintains breast cancer stem cell traits by activating YAP signaling. (A and B) YAP mRNA and protein levels in cell lines with SRGN knockdown were detected by qRT-PCR and Western blotting, respectively. Student's t-test; mean ± s.d. (n=3), _**** p < 0.0001. (C) Immunofluorescence detection of YAP protein expression and nuclear translocation in MCF-7 cells with SRGN overexpression. Scale bar, 20μm. (D) The direct read-out of YAP transactivity was determined using a synthetic YAP/TAZ-responsive luciferase reporter (8XGTIIC-lux). Student's t-test; mean ± s.d. (n=3), _**** p < 0.0001. (E) The percentage of CD44^high/CD24^low cells was determined by flow cytometry and the mammosphere-forming ability was assessed in MCF-7/5-Fu cells with SRGN and YAP expression interference. Scale bar, 100 μm. Student's t-test; mean ± s.d. (n=3), _*** p < 0.001. (F) The percentage of CD44^high/CD24^low cells was determined by flow cytometry and the mammosphere-forming ability was assessed in MCF-7 cells with SRGN and YAP expression interference. Scale bar, 100 μm. Student's t-test; mean ± s.d. (n=3), _** p < 0.01, _*** p < 0.001.